GU Cancers 2025 | ENZA-p: OS and QoL of 177Lu-PSMA-617 and enzalutamide in mCRPC

Omid Yazdanpanah • 14 Feb 2025

GU Cancers 2025

Omid Yazdanpanah, MD, University of California, Irvine, CA, comments on the potential of radioligands with androgen receptor pathway inhibitors (ARPIs) in treating metastatic castration-resistant prostate cancer. The ENZA-p study (NCT04419402) of 177Lu-PSMA-617 and enzalutamide displayed enhanced PSA progression-free survival, radiographic progression-free survival, and overall survival, which align with the findings from the VISION trial (NCT03511664). This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.